longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Merck

MKKGY

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 23.81, within the reasonable range, cheaper than 38.91% of the time in the past 5 years, and the industry ranks 41/257, the industry Median -1.30.

23.81xP/E
$30.14Stock price
$1.27Earnings per share
23.81xP/E
Stock price$30.14Earnings per share$1.27

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
22.59x
Typical range
19.18x–25.17x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
RHHBYUSRoche
22.52x--$348.22B
RHHVFUSROCHE HOLDINGS AG
24.29x--$375.59B
NVSUSNOVARTIS AG
21.00x1.82%$267.85B
AZNUSAstraZeneca
24.67x--$257.67B
SNYUSSanofi
22.50x20.80%$103.37B
SNYNFUSSanofi
22.64x--$104.04B
CHGCYUSChugai Pharmaceutical
23.38x--$70.42B
MKKGYUSMerck
23.81x--$65.52B
DSNKYUSDaiichi Sankyo
20.42x--$34.30B
RDYUSDr Reddys Laboratories
28.18x11.31%$10.15B
LGNDUSLigand Pharmac-B
28.78x14.55%$5.68B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.